CoChat

An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum

Open access
Van Hulle, Carol, Jonaitis, Erin M., Betthauser, Tobey J., Batrla, Richard, Wild, Norbert, Kollmorgen, Gwendlyn, Andreasson, Ulf, Okonkwo, Ozioma, Bendlin, Barbara B., Asthana, Sanjay, Carlsson, Cynthia M., Johnson, Sterling C., Zetterberg, Henrik, Blennow, Kaj · 2021 · Alzheimer's & Dementia
Cited by 138

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Introduction: This study examines the utility of a multipanel of cerebrospinal fluid (CSF) biomarkers complementing Alzheimer's disease (AD) biomarkers in a clinical research sample. We compared biomarkers across groups defined by clinical diagnosis and pTau 181/Aβ 42 status (+/−) and explored their value in predicting cognition. Methods: CSF biomarkers amyloid beta (Aβ)42, pTau 181, tTau, Aβ 40, neurogranin, neurofilament light (NfL), α‐synuclein, glial fibrillary acidic protein (GFAP), chitinase‐3‐like protein 1 (YKL‐40), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), S100 calcium binding protein B (S100B), and interleukin 6 (IL6), were measured with the NeuroToolKit (NTK) for 720 adults ages 40 to 93 years (mean age = 63.9 years, standard deviation [SD] = 9.0; 50 with dementia; 54 with mild cognitive impairment [MCI], 616 unimpaired). Results: Neurodegeneration and glial activation biomarkers were elevated in pTau 181/Aβ 42+ MCI/dementia participants relative to all pTau 181/Aβ 42‐ participants. Neurodegeneration biomarkers increased with clinical severity among pTau 181/Aβ 42+ participants and predicted worse cognitive performance. Glial activation biomarkers were unrelated to cognitive performance. Discussion: The NTK contains promising markers that improve the pathophysiological characterization of AD. Neurodegeneration biomarkers beyond tTau improved statistical prediction of cognition and disease stages.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/alz.12204

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 138

Metadata

Authors
Van Hulle, C., Jonaitis, E. M., Betthauser, T. J., Batrla, R., Wild, N., Kollmorgen, G., Andreasson, U., Okonkwo, O., Bendlin, B. B., Asthana, S., Carlsson, C. M., Johnson, S. C., Zetterberg, H., & Blennow, K.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2020-12-18
Volume
17
Issue
3
Pages
431-445
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W3112012188
Cited by
138
References
23
FWCI
11.81
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. https://app.cochat.ai/papers/10.1002/alz.12204
The paper
Van Hulle, C., Jonaitis, E. M., Betthauser, T. J., Batrla, R., Wild, N., Kollmorgen, G., Andreasson, U., Okonkwo, O., Bendlin, B. B., Asthana, S., Carlsson, C. M., Johnson, S. C., Zetterberg, H., & Blennow, K. (2021). An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. Alzheimer's & Dementia. https://doi.org/10.1002/alz.12204

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.